NKTR · Nektar Therapeutics
$68.67
+3.83 (+5.91%)
At close · Jul 21
Market Cap
$2.32B
Shares
33.79M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$55.23M
-43.9%
FY2025
Net Income
-$164.08M
-37.9%
FY2025
Gross Margin
100%
+31.2pp
FY2025
Operating Margin
-253.66%
-146.8pp
FY2025
Diluted EPS
-$9.73
-12.1%
FY2025
Operating Cash Flow
-$208.51M
-18.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $55.63M | $55.23M | $98.43M | $90.12M | $92.06M | $101.91M | $152.92M | $114.62M | $1.19B | $307.71M | $165.44M | $230.78M | $200.71M | $148.92M | $81.19M | $71.48M | $159.04M | $71.93M | |
| — | $0 | $30.69M | $33.77M | $21.64M | $24.9M | $19.48M | $21.37M | $24.41M | $30.55M | $30.22M | $34.1M | $28.53M | $38.51M | $30.43M | $21.89M | $25.67M | $30.95M | |
| — | $55.23M | $67.74M | $56.35M | $70.42M | $77.01M | $133.44M | $93.24M | $1.17B | $277.16M | $135.22M | $196.68M | $172.17M | $110.41M | $50.76M | $49.59M | $133.37M | $40.98M | |
| — | 100% | 68.82% | 62.53% | 76.5% | 75.57% | 87.26% | 81.35% | 97.95% | 90.07% | 81.74% | 85.22% | 85.78% | 74.14% | 62.52% | 69.37% | 83.86% | 56.98% | |
| $122.53M | $117.33M | $120.91M | $114.16M | $218.32M | $400.27M | $408.68M | $434.57M | $399.54M | $268.46M | $203.8M | $182.79M | $147.73M | $190.01M | $148.68M | $126.77M | $108.07M | $95.11M | |
| $57.77M | $68.67M | $76.75M | $77.42M | $92.33M | $122.84M | $104.68M | $98.71M | $81.44M | $52.36M | $44.28M | $43.27M | $40.93M | $40.53M | $41.61M | $46.76M | $40.99M | $41.01M | |
| — | $1.03M | $4.1M | $7M | $12.2M | $13M | $12.5M | $11M | $8.8M | $12.6M | $13.2M | $11.4M | $12.93M | $14.28M | $14.51M | $14.95M | $16.55M | $14.88M | |
| $190.25M | $195.33M | $203.63M | $353.81M | $468.22M | $548.01M | $578.03M | $554.65M | $505.39M | $367.35M | $278.29M | $260.16M | $217.19M | $269.05M | $222.39M | $195.42M | $187.29M | $167.06M | |
| -$134.62M | -$140.1M | -$105.2M | -$263.68M | -$376.17M | -$446.1M | -$425.11M | -$440.04M | $687.93M | -$59.64M | -$112.86M | -$29.37M | -$16.49M | -$120.13M | -$141.2M | -$123.94M | -$28.26M | -$95.13M | |
| — | -253.66% | -106.88% | -292.59% | -408.63% | -437.76% | -278% | -383.92% | 57.65% | -19.38% | -68.22% | -12.73% | -8.21% | -80.67% | -173.91% | -173.39% | -17.77% | -132.25% | |
| — | -$139.08M | -$101.1M | -$256.68M | -$363.97M | -$433.1M | -$412.61M | -$429.04M | $696.73M | -$47.04M | -$99.66M | -$17.97M | -$3.56M | -$105.86M | -$126.69M | -$108.99M | -$11.7M | -$80.25M | |
| — | — | — | — | $0 | $0 | $6.85M | $21.31M | $21.58M | $22.09M | $22.47M | $18.28M | $17.87M | $18.45M | $15.49M | $10.22M | $11.17M | $12.18M | |
| $11.81M | $10.44M | $14.5M | $19.01M | $6.78M | $2.73M | — | — | — | — | — | — | — | $732K | $2.32M | $2.24M | $1.55M | $3.69M | |
| -$17.59M | -$15.39M | -$14M | -$12.57M | $11.18M | -$77.18M | -$18.84M | -$19K | -$5.21M | -$36.43M | -$39.79M | -$51.3M | -$37.94M | -$39.64M | -$30.25M | -$9.02M | -$8.8M | -$7.64M | |
| -$6.02M | -$8.73M | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$160.94M | -$164.21M | -$119.2M | -$276.26M | -$364.98M | -$523.28M | -$443.95M | -$440.05M | $682.73M | -$96.08M | -$152.65M | -$80.67M | -$54.43M | -$159.77M | -$171.45M | -$132.96M | -$37.06M | -$102.77M | |
| -$126K | -$138K | -$239K | -$200K | $3.22M | $557K | $493K | $613K | $1.41M | $616K | $876K | $506K | -$512K | $2.25M | $406K | $1.02M | $881K | -$253K | |
| -$158.1M | -$164.08M | -$118.96M | -$276.06M | -$368.2M | -$523.84M | -$444.44M | -$440.67M | $681.31M | -$96.69M | -$153.52M | -$81.18M | -$53.92M | -$162.01M | -$171.86M | -$133.98M | -$37.94M | -$102.52M | |
| — | -297.07% | -120.86% | -306.31% | -399.98% | -514.03% | -290.65% | -384.47% | 57.09% | -31.42% | -92.8% | -35.17% | -26.86% | -108.79% | -211.67% | -187.43% | -23.85% | -142.52% | |
| -$159.17M | -$164.12M | -$118.98M | -$269.07M | -$370.95M | -$525.7M | -$445.73M | -$435.36M | $677.11M | -$96.44M | -$153.72M | -$81.78M | -$54.3M | -$162.84M | -$171.11M | -$136.05M | -$38M | -$102.93M | |
| USD/shares | — | -$9.73 | -$8.68 | -$21.75 | -$29.55 | -$42.90 | -$37.35 | -$37.80 | $60.30 | -$9.30 | -$16.50 | — | — | — | — | — | — | — |
| USD/shares | — | -$9.73 | -$8.68 | -$21.75 | -$29.55 | -$42.90 | -$37.35 | -$37.80 | $56.70 | -$9.30 | -$16.50 | — | — | — | — | — | — | — |
| shares | — | 16.87M | 13.71M | 12.67M | 12.48M | 12.22M | 11.91M | 11.67M | 11.31M | 10.4M | 9.31M | 8.83M | 8.46M | 7.72M | 7.65M | 7.53M | — | — |
| shares | — | 16.87M | 13.71M | 12.67M | 12.48M | 12.22M | 11.91M | 11.67M | 12.01M | 10.4M | 9.31M | 8.83M | 8.46M | 7.72M | 7.65M | 7.53M | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2025: $3M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.68×
EV/EBIT
—
Biotechnology median 26.56×
P/E (TTM)
—
Biotechnology median 7.21×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Non Cash Royalty Revenue Related to Sale of Future Royalties | $54,932,000 | $64,267,000 | $68,921,000 | $69,794,000 | $77,746,000 | $48,563,000 | $36,303,000 | $33,308,000 |
| Non-Cash Royalties | $54,900,000 | $64,300,000 | $68,900,000 | — | — | — | — | — |
| License Collaboration and Other Revenue | $300,000 | $597,000 | $520,000 | $1,913,000 | $436,000 | $55,849,000 | $16,975,000 | $1,097,265,000 |
| Product | $0 | $33,563,000 | $20,681,000 | $20,348,000 | $23,725,000 | $17,504,000 | $20,117,000 | $20,774,000 |
| Cash and Non-Cash Royalties | — | — | $68,900,000 | $69,800,000 | $77,700,000 | $79,600,000 | $77,500,000 | — |
| Royalty | — | — | — | $0 | $0 | $30,999,000 | $41,222,000 | $41,976,000 |
Key facts
CIK
906709
CUSIP
640268306
13F (30d)
13 filings
13 filers
Visit website
Investor relations